273 related articles for article (PubMed ID: 15532987)
21. Pneumococcal conjugate vaccines. A review.
Galiza EP; Heath PT
Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.
O'Brien KL; Moulton LH; Reid R; Weatherholtz R; Oski J; Brown L; Kumar G; Parkinson A; Hu D; Hackell J; Chang I; Kohberger R; Siber G; Santosham M
Lancet; 2003 Aug; 362(9381):355-61. PubMed ID: 12907008
[TBL] [Abstract][Full Text] [Related]
24. [Value of pneumococcal vaccination in infants and young children].
Adam D; Scholz H
Klin Padiatr; 2001; 213(3):109-13. PubMed ID: 11417363
[TBL] [Abstract][Full Text] [Related]
25. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain.
Muñoz-Almagro C; Ciruela P; Esteva C; Marco F; Navarro M; Bartolome R; Sauca G; Gallés C; Morta M; Ballester F; Raga X; Selva L;
J Infect; 2011 Aug; 63(2):151-62. PubMed ID: 21679725
[TBL] [Abstract][Full Text] [Related]
26. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?
van Kempen MJ; Vermeiren JS; Vaneechoutte M; Claeys G; Veenhoven RH; Rijkers GT; Sanders EA; Dhooge IJ
Int J Pediatr Otorhinolaryngol; 2006 Feb; 70(2):275-85. PubMed ID: 16140397
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal conjugate vaccines: epidemiology guides clinical use.
Heininger U
Klin Padiatr; 2011 Mar; 223(2):59-60. PubMed ID: 21432762
[No Abstract] [Full Text] [Related]
29. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
30. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
Toltzis P; Jacobs MR
Infect Dis Clin North Am; 2005 Sep; 19(3):629-45. PubMed ID: 16102653
[TBL] [Abstract][Full Text] [Related]
31. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
[TBL] [Abstract][Full Text] [Related]
32. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.
Joloba ML; Windau A; Bajaksouzian S; Appelbaum PC; Hausdorff WP; Jacobs MR
Clin Infect Dis; 2001 Nov; 33(9):1489-94. PubMed ID: 11588694
[TBL] [Abstract][Full Text] [Related]
33. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
Arifeen SE; Saha SK; Rahman S; Rahman KM; Rahman SM; Bari S; Naheed A; Mannan I; Seraji MH; Ahmed NU; Hassan MS; Huda N; Siddik AU; Quasem I; Islam M; Fatima K; Al-Emran H; Brooks WA; Baqui AH; Breiman RF; Sack D; Luby SP
Clin Infect Dis; 2009 Mar; 48 Suppl 2():S103-13. PubMed ID: 19191605
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California.
Black S; Shinefield H
Eur J Pediatr; 2002 Dec; 161 Suppl 2():S127-31. PubMed ID: 12494258
[TBL] [Abstract][Full Text] [Related]
35. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.
Hausdorff WP; Bryant J; Kloek C; Paradiso PR; Siber GR
Clin Infect Dis; 2000 Jan; 30(1):122-40. PubMed ID: 10619741
[TBL] [Abstract][Full Text] [Related]
36. Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis.
Brandileone MC; de Andrade AL; Di Fabio JL; Guerra ML; Austrian R
J Infect Dis; 2003 Apr; 187(8):1206-12. PubMed ID: 12695999
[TBL] [Abstract][Full Text] [Related]
37. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
38. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.
Prymula R; Schuerman L
Expert Rev Vaccines; 2009 Nov; 8(11):1479-500. PubMed ID: 19863240
[TBL] [Abstract][Full Text] [Related]
39. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo.
Traore Y; Tameklo TA; Njanpop-Lafourcade BM; Lourd M; Yaro S; Niamba D; Drabo A; Mueller JE; Koeck JL; Gessner BD
Clin Infect Dis; 2009 Mar; 48 Suppl 2():S181-9. PubMed ID: 19191614
[TBL] [Abstract][Full Text] [Related]
40. [7-valent conjugate Pneumococcal vaccine and nasopharyngeal cavity].
Piffer S
Ann Ig; 2002; 14(6 Suppl 7):31-7. PubMed ID: 12638362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
